Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2289MR)

This product GTTS-WQ2289MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2289MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10063MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ15026MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ1793MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ3147MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ8134MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ11428MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ1408MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ7708MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW